ClinicalTrials.gg

Exelixis clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 57 studies whose lead sponsor is Exelixis. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 16, 2026.

Our grouping of 1 registry name, not the registry’s. See them and correct one ↓

Compare Exelixis with Bayer and Novartis →

Pipeline: 4 programs

Each counted once: 4 with a study Exelixis leads registered in the last two years.

  • Phase 1
  • Phase 3
  • Phase 4 (approved, new studies)

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Exelixis’s own registered studies; Exelixis’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Exelixis’s studies test, most open studies first — 11 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 1 more

Coming up

6 of Exelixis’s studies under way reach primary completion within a year, 1 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 1N’26
  2. 1D
  3. 1J’27
  4. F
  5. M
  6. 1A
  7. 1M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. 1N

Add all 6 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 18, 2026.

All 57 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1119%Recruiting 9 · Enrolling by invitation 1 · Not yet recruiting 1
  • Under way, not recruiting1119%
  • Completed1832%
  • Stopped early1628%Terminated 14 · Withdrawn 1 · Suspended 1
  • Status unknown or other12%

Phase

  • Phase 133
  • Phase 315
  • Phase 210
  • Phase 41

Where

  • United States54
  • United Kingdom19
  • France17
  • Spain17
  • Australia17
  • Italy16

Over the years

  1. 807
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 526

By the year each study started; 3 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Exelixis.

  • Exelixis
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    57 studies

Focus areas

Conditions Exelixis leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 57. Browse all 57 →